Evidence-based · For women
The research on peptides,
decoded.
Published studies. Actual mechanisms. What the trials showed — and what they didn't. Built for women doing serious research.
Start here
Not sure which compounds
match your goals?
Answer 4 questions about your research focus — skin health, metabolic, cognitive, hormonal — and we'll surface the most relevant compounds with research profiles and references.
Take the quiz →New
Peptide research
and menopause.
Hot flashes, weight gain, brain fog, skin, libido, joint pain — mapped to the published research. Which compounds are relevant, why, and what the data actually shows.
Read the research →Hot flashes
Kisspeptin
Weight gain
Semaglutide
Brain fog
Semax
Skin & collagen
GHK-Cu
Libido
PT-141
Sleep
Epitalon
About this site
Built for the woman
doing her own research.
Most peptide content is written for competitive athletes or buried behind journal paywalls. Peptide Girlies pulls from the same published studies — Phase III trials, regulatory approvals, preclinical data — and makes them readable.
We cover mechanism, evidence quality, what the data actually shows for women, and where to source research-grade material. No bro-science. No hype. Just the data, with context.
Compound Library
Where most women start
Semaglutide
metabolicA long-acting GLP-1 receptor agonist with extensive clinical trial data for type 2 diabetes and obesity, among the most-studied peptide therapeutics in the world.
GHK-Cu
healingA naturally occurring copper-binding tripeptide with extensive research in wound healing, collagen synthesis, and skin remodeling.
PT-141
cosmeticA cyclic heptapeptide melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Selank
cognitiveA synthetic heptapeptide analog of tuftsin developed in Russia, studied for anxiolytic, nootropic, and immunomodulatory effects with a favorable tolerability profile.
BPC-157
healingA 15-amino-acid synthetic peptide derived from a gastric protein, widely studied for tissue repair and healing applications.
Tirzepatide
metabolicA dual GIP/GLP-1 receptor agonist developed by Eli Lilly showing the largest weight loss results of any peptide therapeutic in clinical trials to date.
Stay updated
New research, straight to you.
New compound profiles, updated price data, and women's health research — weekly. No noise.
All content is for educational and research reference only. Nothing constitutes medical advice or a recommendation for human consumption. Read the full disclaimer →